The diagnostic utility of inhibin staining in ovarian neoplasms

International Journal of Gynecological Pathology

Volumn 17, Issue 2, 1998, Pages 97-105

  Pelkey, Timothy J ^a   Frierson Jr , Henry F ^a   Mills, Stacey E ^a   Stoler, Mark H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Immunohistochemistry; Inhibin; Ovary; Sex cord stromal tumors

Indexed keywords

INHIBIN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY METASTASIS; PRIORITY JOURNAL; SEX CORD TUMOR;

EID: 0031948924     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199804000-00001     Document Type: Article

References (79)

1. Vale W, Rivier C, Hsueh A, et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 1989;44:1-35.
2. Burger HG. Clinical utility of inhibin measurements. J Clin Endocrinol Metab 1993;76:1391-6.
3. Burger HG. Inhibin. Reprod Med Rev 1992;1:1-20
4. Healy DL, Mamers P, Bangah M, Burger HG. Clinical and pathophysiologic aspects of inhibin. Hum Reprod 1993;8 (Suppl 2):138-40.
5. Burger HG, Robertson DM, Cahir N, et al. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin Endocrinol 1996;44:413-8.
6. Qu J, Thomas K. Inhibin and activin production in human placenta. Endocr Rev 1995;16:485-507.
7. Mayo KE, Cerelli GM, Spiess J, et al.. Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci USA 1986;83;5849-53.
8. Rao Veeramachaneni DN, Schanbacher BC, Amann RP. Immunolocalization and concentrations of inhibin alpha in the ovine testis and excurent duct system. Biol Reprod 1989;41-499-503.
9. Haji M, Nishi Y, Tanaka S, et al. Evidence for the secretion of inhibin-like immunoreactivity from cultured human adrenal cells. J Endocrinol 1991;128:R13.
10. Spencer SJ, Rabinovici J, Mesiano S, Goldsmith PC, Jaffe RB. Activin and inhibin in the human adrenal gland. J Clin Invest.
11. Merchenthaler I, Culler MD, Petrusz P, Negro-Vilar A. Immunocytochemical localization of inhibin in rat and human reproductive tissues. Mol Cell Endocrinol 1987;54:239-43.
12. DeJong FH, Grootenhuis AJ, Steenbergen J, et al. Inhibin immunoreactivity in gonadal and non-gonadal tumors. J Steroid Biochem Mol Biol 1990;37:863-6.
13. Alvarado MV, Russo J, Russo IH. Immunolocalization of inhibin in the mammary gland of rats treated with hCG. J Histochem Cytochem 1993;41:29-34.
14. Ying S-Y, Zhang Z. Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Res Treat 1996;37:151-60.
15. Wada M, Shintani Y, Kosaka M, Sano T, Hizawa K, Saito S. Immunohistochemical localization of activin A and follistatin in human tissues. Endocrine J 1996;43:375-85.
16. Cuevas P, Ying SY, Ling N, Ueno N, Esch F, Guillemin R. Immunohistochemical detection of inhibin in the gonad. Biochem Biophys Res Commun 1987;142:23-30.
17. Petraglia F, Ancheschi MM, Calza L, et al. Inhibin and activin in human fetal membranes: evidence for a local effect on prostaglandin release. J Clin Endocrinol Metab 1993;77-542-8.
18. Petraglia F, Garuti GC, Calza L, et al. Inhibin subunits in human placenta: localization and messenger ribonucleic acid levels during pregnancy. Am J Obstet Gynecol 1991;165-750-8.
19. Petraglia F, Calza L, Garuti GC, et al. Presence and synthesis of inhibin subunits in human decidua. J Clin Endocrinol Met 1990; 71:487-92.
20. Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin-activin subunits in hydatidiform mole and invasive mole. Obstet Gynecol 1993;82:414-8.
21. de Jong FH, de Winter JP, Wesseling JG, et al. Inhibin subunits, follistatin and activin receptors in the human teratocarcinoma cell line TERA-2. Biochem Biophvs Res Comm 1993-192:1334-9.
22. Sawchenko PE, Plotsky PM, Pfeiffer SW, et al. Inhibin Beta in central neural pathways involved in the control of oxytocin secretion. Nature 1988;334:615-7.
23. Meunier H, Rivier C, Evans RM, Vale W. Gonadal and extragonadal expression of inhibin alpha, beta A, beta B subunits in various tissues predicts diverse functions. Proc Natl Acad Sci USA 1988;85:247-51.
24. Antonipillai I, Wahe M, Yamamoto J, Horton R. Activin and inhibin have oppositve effects on steroid 5 alpha-reductase activity in genital skin fibroblasts. Mol Cell Endocrinol 1995;107:99-104.
25. Yu J, Shao L, Lemas V, et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 1987;330-765-7.
26. Hedger MP, Drummond AE, Robertson DM, Risbridger GP, de Kretser DM. Inhibin and activin regulate [3-H]thymidine uptake by rat thymocytes and 3T3 Cells in vitro. Mol Cell Endocrinol 1989;61:133-8.
27. Hangoc G, Carow CE, Schwall R, Mason AJ, Broxmeyer HE. Effects in vivo of recombinant human inhibin on myelopoiesis in mice. Exp Hematol 1992;20:1243-6.
28. Roberts VJ, Barth S, El-Roeiy ASC, Yen S. Expression of inhibin/ activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Met 1993;77:1402-10.
29. Matzuk MM, Kumar TR, Shou W, et al. Transgenic models to study the roles of inhibins and activings in reproduction, oncogenesis, and development. Recent Prog Horm Res 1996;51:123-54.
30. Matzuk MM, Finegold MJ, Su JGJ, Hsueh A, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992;360:313-9.
31. Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995;71:1046-50.
32. Burger HG, Robertson DM, Cahir N, Mamers P, Healy CL, Jobling T, Groome N. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin Endocrinol 1996;44:413-8.
33. Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn H. Inhibin as a marker for granulosa-cell tumors. N Eng J Med 1989;321:790-3.
34. Jobling T, Mamers P, Healy DL, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 1994; 55:285-9.
35. Nishida M, Jimi S, Haji M, Hayashi I, Kai T, Tasaka H. Juvenile granulosa cell tumor in association with a high serum inhibin level. Gynecol Oncol 1991;40:90-4.
36. Sluijmer AV, Heineman MJ, Evers JLH, de Jong FH. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a post-menopausal patient with a granulosa cell tumour. Acta Endocrinol 1993;129:311-4.
37. Badonnel Y, Barbe F, Legagneur H, Poncelet E, Schweitzer M. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta subunit. Clin Endocrinol 1994;41-155-62.
38. Yohkaichiya T, Fukaya T, Hoshiai H, Yajima A, deKretser DM. Inhibin: a new circulating marker of hydatidiform mole? Br Med J 1989;298:1684-5.
39. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143.
40. Healy DL, Burger HG, Mamers P. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993;329:1539-42.
41. Burger HG. Inhibin as a tumour marker. Commentary. Clin Endocrinol 1994;41:151-3.
42. Blaaker J, Micic S, Morris ID, et al. Immunoreactive inhibinproduction in post-menopausal women with malignant epithelial ovarian tumors. Eur J Obstet Gynecol Rep Biol 1993;52:105-10.
43. Blaakaer J, Hogdall CK, Micic S, et al. Ovarian carcinoma serum markers and ovarian steroid activity - is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. Eur J Obstet Gynecol Rep Biol 1995;59:53-6.
44. Ohashi M, Hasegawa Y, Haji M, Igarashi M, Nawata H. Production of immunoreactive inhibin by a virilizing ovarian tumour (Sertoli-Leydig tumour). Clin Endocrinol 1990;33:613-8.
45. Puls LE, Hamous J, Morrow MS, Schneyer A, MacLaughlin DT, Castracane VD. Recurrent ovarian sex cord tumor with annular tubules: tumor marker and chemotherapy experience. Gynecol Oncol 1994;54:396-401.
46. Silvermen LA, Gitelman SE. Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. J Pediatr 1996;129:918-21.
47. Key RA, Lhomme C, Marcillac I, et al. Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 1996;174:958-65.
48. Wallace EM, Healy DL. Inhibins and activins: roles in clinical practice. Br J Obstet Gynaecol 1996;103:945-56.
49. Rishi M, Howard LN, Bratthauer GL, Tavassoli FA. Use of a monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 1997;21: 583-9.
50. Fleming P, Grothe W, Maschek H, Petry KU, Wellmann A, Georgii A. The site of inhibin production in ovarian neoplasms. Histopathology 1996;29:465-8.
51. Fleming P, Wellmann A, Maschek H, Lang H, Georgii A. Monoclonal antibodies against inhibin represent key markers of adult granulosa cell tumors of the ovary even in their metastases. Am J Surg Pathol 1995;19:927-33.
52. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 1995;57:27-32.
53. Ames PF, Roth LM, Walls J, Costa MJ. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective diagnostic tool. Mod Pathol 1997;1:96A.
54. Hussong J, Woodruff T, Keh PC. Immunohistochemical study of primary ovarian tumors with inhibin antibody. Mod Pathol 1997; 1:102A.
55. Zheng W, Sung CJ, Hanna I, et al. α and β subunits of inhibin/ activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997;16:263-71.
56. Stewart CJR, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology 1997;31:67-74.
57. Gaffey MJ, Frierson HF, Iezzoni JC, et al. Ovarian granulosa cell tumor with bizarre nuclei: an immunohistochemical analysis. Mod Pathol 1996;9:308-15.
58. Young RH, Scully RE. Sex cord-stromal, steroid Cell, and other ovarian tumors with endocrine, paraendocrine and paraneoplastic manifestations. In: Kurman RJ (ed). Blaustein's Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag Inc., 1994:783-847.
59. McLachlan RI, Robertson DM, Healy DL, Burger HG, DeKretser DM. Circulating immunoreactive inhibin levels during the normal human menstrual cycle. J Clin Endocrinol Metab 1987;65:954-61.
60. Roseff SJ, Bangah ML, Kettel LM, Vale W, Rivier J, Burger HG, Yen SSC. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab 1989;69:1033-9.
61. Robertson DM, Sullivan J, Watson M, Cahir N. Inhibin forms in human plasma. J Endocrinol 1995;144:261-9.
62. Robertson DM, Tsonis CG, McLachlan RI, et al. Comparison of inhibin immunological and in vitro biological activities in human serum. J Clin Endocrinol Metab 1988;67:438-48.
63. Yamoto M, Minami S, Nakano R, Kobayashi M. Immunohistochemical localization of inhibin/activin subunits in human ovarian follicles during the menstrual cycles. J Clin Endocrinol Metab 1992;74:989-93.
64. Yamoto M, Minami S, Nakano R. Immunohistochemical localization of inhibin subunits in human corpus lutea during menstrual cycle and pregnancy. J Clin Endocrinol Metab 1991;73:470-7.
65. Roberts VJ, Barth S, El-Roeiy A, Yen SSC. Expression of inhibin/ activin subunits, follistatin mRNAs and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 1993;77:1402-10.
66. Ogawa K, Abe K, Kurosawa N, et al. Expression of alpha, betaA and betaB subunits of inhibin or activin and follistatin in rat pancreatic islets. FEBS Letters 1993;319:217-20.
67. Gitsch G, Kohlberger P, Hanzal E, Kolbl H, Breitenecker G. Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet 1991;249: 173-7.
68. Benjamin E, Law S, Bobrow LG. Intermediate filaments cytokeratin and vimentin in ovarian sex cord-stromal tumours with correlative studies in adult and fetal ovaries. J Pathol 1987;152:253-63.
69. Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. Int J Gynecol Pathol 1989; 8:364-73.
70. Costa MJ, DeRose PB, Roth LM, Brescia RJ, Zaloudek CJ, Cohen C. Immunohistochemical phenotype of ovarian granulosa cell tumors: Absence of epithelial membrane antigen has diagnostic value. Hum Pathol 1994;25:60-6.
71. Chadha S, van der Kwast TH. Immunohistochemistry of ovarian granulosa cell tumours. Virchows Archiv A Pathol Anat 1989;414: 439-45.
72. Santini D, Ceccarelli C, Leone O, et al. Smooth muscle differentiation in normal human ovaries, ovarian stromal hyperplasia and ovarian granulosa-stromal cell tumors. Mod Pathol 1995;8:25-30.
73. Chadha S, Rao BR, Slotman BJ, van Vroonhoven J, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993;24:90-5.
74. Lantta M, Estradiol and progesterone receptors in normal ovary and ovarian tumors. Acta Obstet Gynecol Scand 1984;63:497-503.
75. Otis CN, Powell JL, Barbuto D, Carcangiu ML. Intermediate filamentous proteins in adult granulosa cell tumors. Am J Surg Pathol 1992;16:962-8.
76. Bychkov V, Deligdisch L, Talerman A, Reddy VB. Lectin histochemistry of sex cord-stromal tumors and small cell carcinoma of the ovaries. Gynecol Obstet Invest 1992;34:115-8.
77. Zheng W, Welt C, Lambert-Messerlian G, Sung CJ, Schneyer AL, Felix JC. Asymmetric expression of inhibin and activin in ovarian epithelial carcinoma. Mod Pathol 1997;1:112A.
78. Clement PB. Nonneoplastic lesions of the ovary. In: Kurman RJ (ed). Blaustein's Pathology of the Female Genital Tract 4th ed. New York: Springer-Verlag Inc., 1994:597-645.
79. Rutgers J, Scully RE. Functional ovarian tumors with peripheral steroid cell proliferation: a report of twenty-four cases. Int J Gynecol Pathol 1986;5:319-37.